Company

Heidelberg Pharma

As of the edition of 20 October 2026, Heidelberg Pharma runs 6 drugs; it is on route A at 6 targets and on route B at 0 targets.

Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.

Drugs by status

Route A at 6 targets, route B at 0 targets.

Three of its 6 rows, by target and route
Target	Route
MAP2K2 Dual specificity mitogen-activated protein kinase kinase 2	Route A
MAP2K1 Dual specificity mitogen-activated protein kinase kinase 1	Route A
PIK3CB Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Route A

In the product

6 company-target rows on route A or B; 3 are not shown here, and no score is.